Last reviewed · How we verify
NCT07096648: WARD-HOME I
Alert Burden When Monitoring Patients at Home
trial testing Continuous vital sign monitoring in Continuous Monitoring in 110 participants. Participants enrolled and being followed up; not accepting new ones.
1 September 2025
Quick facts
| Lead sponsor | Bispebjerg Hospital |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 110 |
| Start date | 16 June 2025 |
| Primary completion | 1 September 2025 |
| Estimated completion | 1 December 2025 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Continuous vital sign monitoring
Conditions studied
- Continuous Monitoring — all drugs for Continuous Monitoring →
- Vital Signs Monitoring — all drugs for Vital Signs Monitoring →
- Hospital at Home — all drugs for Hospital at Home →
- Remote Monitoring — all drugs for Remote Monitoring →
Sponsor
Bispebjerg Hospital
Who can join
18 and older, any sex, with Continuous Monitoring or Vital Signs Monitoring. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this observational study is to evaluate the burden and clinical relevance of vital sign alerts during home monitoring in recently discharged medical patients. The primary outcome is the total number of vital sign alerts per patient per day. Secondary outcomes include the number of alerts per specific vital sign parameter, the frequency of alerts during daytime versus evening and nighttime, and the peak alert time during the day. We will compare alert data without filtering to data processed with AI-driven filtering methods to assess if these filters reduce the number of non-actionable alerts while maintaining clinical relevance. Participants will be equipped with wearable devices to continuously monitor heart rate, respiratory rate, blood pressure, and oxygen saturation during the first days after hospital discharge. Vital signs will be transmitted remotely, and alerts will be generated based on predefined thresholds.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07096648
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Continuous vital sign monitoring
Trials testing the same drug.
- NCT06227208 — Postoperative Opioid and Respiratory Depression in Opioid Naive and Chronic Opioid Patients · completed
Other Bispebjerg Hospital trials
Trials by the same sponsor.
- NCT06872060 — The Effects of Glucagon on Renal Regional Blood Flow in Humans Measured by Magnetic Resonance. · NA · not yet recruiting
- NCT07373587 — Preventing Hospital Associated Disability in Older Patients: Individualized Nutrition and Exercise Strategy · NA · not yet recruiting
- NCT07123558 — Anal Cancer Prevention in High-Risk Categories of Men Who Have Sex With Men · NA · not yet recruiting
- NCT07124338 — Preventing Hospital Associated Disability in Older Patients: Individualized Nutrition and Exercise Strategy, a Feasibili · NA · active not recruiting
- NCT06967220 — The Impact of Inflammation on Skeletal Muscle Maintenance in Hospitalized Patients · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07096648 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bispebjerg Hospital
- Last refreshed: 31 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07096648.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing